Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment
The condition of prolonged obstructive jaundice with patent bile ducts was first described in 1851 by Addison and Gull of Guy's Hospital, London. The term primary biliary cirrhosis (PBC) was defined in 1950 by Ahrens and colleagues of the Rockefeller Institute, New York. The condition was consi...
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Dordrecht
Springer Netherlands
1998
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | The condition of prolonged obstructive jaundice with patent bile ducts was first described in 1851 by Addison and Gull of Guy's Hospital, London. The term primary biliary cirrhosis (PBC) was defined in 1950 by Ahrens and colleagues of the Rockefeller Institute, New York. The condition was considered rare but this changed in 1965 with the discovery of a definitive diagnostic serum mitochondrial antibody test and the recognition that a raised serum alkaline phosphatase value, often discovered incidentally, could be a diagnostic pointer. If the diagnosis is made earlier, the end stages are rarely reached as death is replaced by liver transplantation. On November 6th 1997, in Chicago, an International Faculty discussed in depth the clinical features, pathogenesis and treatment of PBC, no longer considered a rare disease. The course of PBC is long, but some 18 years after the discovery of a positive mitochondrial antibody test in a symptom free patient with normal serum biochemistry, 83% will have developed abnormal tests and 76% will be symptomatic. Identification of those who will progress rapidly is difficult. The serum antimitochondrial profile may be useful but this is a very specialist technique. Mathematical prognostic models are useful in therapeutic trials and in the selection and timing of patients for liver transplantation but have limited value in individual patients. An increasing serum bilirubin level remains the most important indicator of rapid progression. Its value however can be negated by the use of ursodeoxycholic acid which has a bilirubin-lowering effect |
| Beschreibung: | 1 Online-Ressource (XV, 176 p) |
| ISBN: | 9789401148849 |
| DOI: | 10.1007/978-94-011-4884-9 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046145058 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1998 |||| o||u| ||||||eng d | ||
| 020 | |a 9789401148849 |9 978-94-011-4884-9 | ||
| 024 | 7 | |a 10.1007/978-94-011-4884-9 |2 doi | |
| 035 | |a (ZDB-2-SME)978-94-011-4884-9 | ||
| 035 | |a (OCoLC)1119007208 | ||
| 035 | |a (DE-599)BVBBV046145058 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.36 |2 23 | |
| 245 | 1 | 0 | |a Primary Biliary Cirrhosis |b From Pathogenesis to Clinical Treatment |c edited by Keith D. Lindor, E. Jenny Heathcote, Raoul Poupon |
| 264 | 1 | |a Dordrecht |b Springer Netherlands |c 1998 | |
| 300 | |a 1 Online-Ressource (XV, 176 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a The condition of prolonged obstructive jaundice with patent bile ducts was first described in 1851 by Addison and Gull of Guy's Hospital, London. The term primary biliary cirrhosis (PBC) was defined in 1950 by Ahrens and colleagues of the Rockefeller Institute, New York. The condition was considered rare but this changed in 1965 with the discovery of a definitive diagnostic serum mitochondrial antibody test and the recognition that a raised serum alkaline phosphatase value, often discovered incidentally, could be a diagnostic pointer. If the diagnosis is made earlier, the end stages are rarely reached as death is replaced by liver transplantation. On November 6th 1997, in Chicago, an International Faculty discussed in depth the clinical features, pathogenesis and treatment of PBC, no longer considered a rare disease. The course of PBC is long, but some 18 years after the discovery of a positive mitochondrial antibody test in a symptom free patient with normal serum biochemistry, 83% will have developed abnormal tests and 76% will be symptomatic. Identification of those who will progress rapidly is difficult. The serum antimitochondrial profile may be useful but this is a very specialist technique. Mathematical prognostic models are useful in therapeutic trials and in the selection and timing of patients for liver transplantation but have limited value in individual patients. An increasing serum bilirubin level remains the most important indicator of rapid progression. Its value however can be negated by the use of ursodeoxycholic acid which has a bilirubin-lowering effect | ||
| 650 | 4 | |a Hepatology | |
| 650 | 4 | |a Clinical medicine | |
| 700 | 1 | |a Lindor, Keith D. |4 edt | |
| 700 | 1 | |a Heathcote, E. Jenny |4 edt | |
| 700 | 1 | |a Poupon, Raoul |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789401060479 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792387404 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789401148856 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-94-011-4884-9 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031525243 | ||
| 966 | e | |u https://doi.org/10.1007/978-94-011-4884-9 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180481255669760 |
|---|---|
| any_adam_object | |
| author2 | Lindor, Keith D. Heathcote, E. Jenny Poupon, Raoul |
| author2_role | edt edt edt |
| author2_variant | k d l kd kdl e j h ej ejh r p rp |
| author_facet | Lindor, Keith D. Heathcote, E. Jenny Poupon, Raoul |
| building | Verbundindex |
| bvnumber | BV046145058 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-94-011-4884-9 (OCoLC)1119007208 (DE-599)BVBBV046145058 |
| dewey-full | 616.36 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.36 |
| dewey-search | 616.36 |
| dewey-sort | 3616.36 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-94-011-4884-9 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03156nmm a2200433zc 4500</leader><controlfield tag="001">BV046145058</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1998 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789401148849</subfield><subfield code="9">978-94-011-4884-9</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-94-011-4884-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-94-011-4884-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119007208</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046145058</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.36</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Primary Biliary Cirrhosis</subfield><subfield code="b">From Pathogenesis to Clinical Treatment</subfield><subfield code="c">edited by Keith D. Lindor, E. Jenny Heathcote, Raoul Poupon</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Dordrecht</subfield><subfield code="b">Springer Netherlands</subfield><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XV, 176 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The condition of prolonged obstructive jaundice with patent bile ducts was first described in 1851 by Addison and Gull of Guy's Hospital, London. The term primary biliary cirrhosis (PBC) was defined in 1950 by Ahrens and colleagues of the Rockefeller Institute, New York. The condition was considered rare but this changed in 1965 with the discovery of a definitive diagnostic serum mitochondrial antibody test and the recognition that a raised serum alkaline phosphatase value, often discovered incidentally, could be a diagnostic pointer. If the diagnosis is made earlier, the end stages are rarely reached as death is replaced by liver transplantation. On November 6th 1997, in Chicago, an International Faculty discussed in depth the clinical features, pathogenesis and treatment of PBC, no longer considered a rare disease. The course of PBC is long, but some 18 years after the discovery of a positive mitochondrial antibody test in a symptom free patient with normal serum biochemistry, 83% will have developed abnormal tests and 76% will be symptomatic. Identification of those who will progress rapidly is difficult. The serum antimitochondrial profile may be useful but this is a very specialist technique. Mathematical prognostic models are useful in therapeutic trials and in the selection and timing of patients for liver transplantation but have limited value in individual patients. An increasing serum bilirubin level remains the most important indicator of rapid progression. Its value however can be negated by the use of ursodeoxycholic acid which has a bilirubin-lowering effect</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical medicine</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lindor, Keith D.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heathcote, E. Jenny</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Poupon, Raoul</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789401060479</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792387404</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789401148856</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-94-011-4884-9</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031525243</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-94-011-4884-9</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046145058 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:27Z |
| institution | BVB |
| isbn | 9789401148849 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031525243 |
| oclc_num | 1119007208 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XV, 176 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1998 |
| publishDateSearch | 1998 |
| publishDateSort | 1998 |
| publisher | Springer Netherlands |
| record_format | marc |
| spelling | Primary Biliary Cirrhosis From Pathogenesis to Clinical Treatment edited by Keith D. Lindor, E. Jenny Heathcote, Raoul Poupon Dordrecht Springer Netherlands 1998 1 Online-Ressource (XV, 176 p) txt rdacontent c rdamedia cr rdacarrier The condition of prolonged obstructive jaundice with patent bile ducts was first described in 1851 by Addison and Gull of Guy's Hospital, London. The term primary biliary cirrhosis (PBC) was defined in 1950 by Ahrens and colleagues of the Rockefeller Institute, New York. The condition was considered rare but this changed in 1965 with the discovery of a definitive diagnostic serum mitochondrial antibody test and the recognition that a raised serum alkaline phosphatase value, often discovered incidentally, could be a diagnostic pointer. If the diagnosis is made earlier, the end stages are rarely reached as death is replaced by liver transplantation. On November 6th 1997, in Chicago, an International Faculty discussed in depth the clinical features, pathogenesis and treatment of PBC, no longer considered a rare disease. The course of PBC is long, but some 18 years after the discovery of a positive mitochondrial antibody test in a symptom free patient with normal serum biochemistry, 83% will have developed abnormal tests and 76% will be symptomatic. Identification of those who will progress rapidly is difficult. The serum antimitochondrial profile may be useful but this is a very specialist technique. Mathematical prognostic models are useful in therapeutic trials and in the selection and timing of patients for liver transplantation but have limited value in individual patients. An increasing serum bilirubin level remains the most important indicator of rapid progression. Its value however can be negated by the use of ursodeoxycholic acid which has a bilirubin-lowering effect Hepatology Clinical medicine Lindor, Keith D. edt Heathcote, E. Jenny edt Poupon, Raoul edt Erscheint auch als Druck-Ausgabe 9789401060479 Erscheint auch als Druck-Ausgabe 9780792387404 Erscheint auch als Druck-Ausgabe 9789401148856 https://doi.org/10.1007/978-94-011-4884-9 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Primary Biliary Cirrhosis From Pathogenesis to Clinical Treatment Hepatology Clinical medicine |
| title | Primary Biliary Cirrhosis From Pathogenesis to Clinical Treatment |
| title_auth | Primary Biliary Cirrhosis From Pathogenesis to Clinical Treatment |
| title_exact_search | Primary Biliary Cirrhosis From Pathogenesis to Clinical Treatment |
| title_full | Primary Biliary Cirrhosis From Pathogenesis to Clinical Treatment edited by Keith D. Lindor, E. Jenny Heathcote, Raoul Poupon |
| title_fullStr | Primary Biliary Cirrhosis From Pathogenesis to Clinical Treatment edited by Keith D. Lindor, E. Jenny Heathcote, Raoul Poupon |
| title_full_unstemmed | Primary Biliary Cirrhosis From Pathogenesis to Clinical Treatment edited by Keith D. Lindor, E. Jenny Heathcote, Raoul Poupon |
| title_short | Primary Biliary Cirrhosis |
| title_sort | primary biliary cirrhosis from pathogenesis to clinical treatment |
| title_sub | From Pathogenesis to Clinical Treatment |
| topic | Hepatology Clinical medicine |
| topic_facet | Hepatology Clinical medicine |
| url | https://doi.org/10.1007/978-94-011-4884-9 |
| work_keys_str_mv | AT lindorkeithd primarybiliarycirrhosisfrompathogenesistoclinicaltreatment AT heathcoteejenny primarybiliarycirrhosisfrompathogenesistoclinicaltreatment AT pouponraoul primarybiliarycirrhosisfrompathogenesistoclinicaltreatment |